Insulet's Omnipod 5 Gets FDA Clearance for Use by Type 2 Diabetes Patients
By Paul Ziobro
Insulet said its Omnipod 5 automated insulin delivery system has been cleared by the Food and Drug Administration for people with type 2 diabetes.
The Acton, Mass.-based company said Monday the approval makes the device the first automated insulin delivery system cleared by the FDA for both type 1 and type 2 diabetes management.
"Today's announcement represents a significant milestone in providing easy-to-use, patient-centric technology for the treatment of type 2 diabetes," Insulet Chief Executive Jim Hollingshead said.
The Omnipod is a wearable, tubeless products that provides up to three days of non-stop insulin delivery without the need to handle a needle. The Omnipod 5, meanwhile, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks and can be controlled by a compatible smartphone in the U.S. or by a controller.
Write to Paul Ziobro at paul.ziobro@wsj.com
(END) Dow Jones Newswires
August 26, 2024 17:00 ET (21:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Should Emerging-Markets Stocks Stand Alone in Your Portfolio?
-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued